Michal Lotem

6PUBLICATIONS
50CO-AUTHORS
Molecular targetsChemotherapyPredictive and prognostic markersSolid tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 23, 2025
Facts and Hopes: Toward the Next Quantum Leap in Melanoma.

Keith T Flaherty, Andrew E Aplin, Michael A Davies

|Mar 21, 2024
Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer.

Petros Christopoulos, Michal Harel, Kimberly McGregor

|Jun 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.

Caroline Robert, Matteo S Carlino, Catriona McNeil

|Jun 07, 2023
Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactions.

Nethanel Friedman, Liza Weinstein-Fudim, Yelena Mostinski

|Jun 05, 2021
TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment.

Martino Maddalena, Giuseppe Mallel, Nishanth Belugali Nataraj

|Oct 12, 2018
Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40.

Noam Levin, Hadas Weinstein-Marom, Aviad Pato

Pageof 1

Frequent Collaborators

2 joint publications

Galit Eisenberg

1 joint publications

Orit Itzhaki

1 joint publications

Giuseppe Mallel

1 joint publications

Nishanth Belugali Nataraj